Get the Stockscreener App
1.01
7.03%
0.0663
After Hours:
1.01
Estrella Immunopharma Inc stock is traded at $1.01, with a volume of 92,431.
It is up +7.03% in the last 24 hours and down -33.55% over the past month.
Estrella Immunopharma Inc is a clinical-stage biopharmaceutical company developing CD19 and CD22-targeted ARTEMIS T-cell therapies with the capacity to address treatment challenges for patients with blood cancers and solid tumors. Estrella's mission is to harness the evolutionary power of the human immune system to transform the lives of patients fighting cancer and autoimmune diseases.
See More
Previous Close:
$0.9437
Open:
$0.94
24h Volume:
92,431
Relative Volume:
0.39
Market Cap:
$38.14M
Revenue:
-
Net Income/Loss:
$-8.82M
P/E Ratio:
-3.3667
EPS:
-0.3
Net Cash Flow:
$-18.01M
1W Performance:
+1.61%
1M Performance:
-33.55%
6M Performance:
+12.22%
1Y Performance:
-14.41%
1-Day Range:
$0.92
$1.06
1-Week Range:
$0.9002
$1.06
52-Week Range:
$0.7301
$3.15
Estrella Immunopharma Inc Stock (ESLA) Company Profile
Name
Estrella Immunopharma Inc
Sector
Industry
Phone
(510) 318-9098
Address
5858 HORTON STREET, SUITE 370, EMERYVILLE
Compare ESLA with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
ESLA
Estrella Immunopharma Inc
|
1.01 | 35.64M | 0 | -8.82M | -18.01M | -0.30 |
|
VRTX
Vertex Pharmaceuticals Inc
|
468.41 | 118.58B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
753.55 | 79.40B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ARGX
Argen X Se Adr
|
814.74 | 51.18B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
357.98 | 48.88B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ONC
Beone Medicines Ltd Adr
|
339.32 | 37.49B | 4.98B | 69.59M | 525.67M | 0.5197 |
Estrella Immunopharma Inc Stock (ESLA) Latest News
How much upside does Estrella Immunopharma Inc have2025 Risk Factors & High Accuracy Swing Trade Signals - baoquankhu1.vn
Is Estrella Immunopharma Inc. stock overvalued or fairly pricedWeekly Stock Report & Daily Volume Surge Signals - bollywoodhelpline.com
Panic Selling: Is Estrella Immunopharma Inc stock a hidden gemWeekly Profit Analysis & Breakout Confirmation Trade Signals - baoquankhu1.vn
Market Outlook: Will Estrella Immunopharma Inc benefit from government policyJuly 2025 Price Swings & Advanced Swing Trade Entry Plans - baoquankhu1.vn
Estrella Immunopharma receives Nasdaq notice for delayed annual meeting By Investing.com - Investing.com South Africa
Estrella Immunopharma receives Nasdaq notice for delayed annual meeting - Investing.com
Estrella Immunopharma Receives Nasdaq Non-Compliance Notice - TipRanks
Estrella Immunopharma Disclosed Failure to Satisfy a Continued Listing Rule or Standard - TradingView — Track All Markets
Day Trade: What insider trading reveals about Estrella Immunopharma Inc stock2025 Investor Takeaways & Expert Curated Trade Setups - Bộ Nội Vụ
Is Estrella Immunopharma Inc. stock a good choice for value investors2025 Dividend Review & Fast Gain Swing Alerts - Улправда
How Estrella Immunopharma Inc. stock trades during market volatilityWeekly Trend Recap & Safe Entry Trade Reports - ulpravda.ru
How risky is Estrella Immunopharma Inc. stock nowPortfolio Value Summary & Technical Buy Zone Confirmations - ulpravda.ru
Estrella Immunopharma, Inc.Warrant (NQ: ESLAW - FinancialContent
Is Estrella Immunopharma Inc. stock a smart buy before Fed meetingWeekly Volume Report & Long-Term Growth Stock Strategies - Улправда
Can Estrella Immunopharma Inc. stock sustain market leadershipWatch List & Short-Term Trading Alerts - ulpravda.ru
Is Estrella Immunopharma Inc. stock attractive for passive investors2025 Geopolitical Influence & Accurate Intraday Trading Signals - ulpravda.ru
Published on: 2026-01-07 23:18:22 - Улправда
How interest rate cuts could boost Estrella Immunopharma Inc. stockSector Leadership Analysis & Small Capital Trading Growth - Улправда
Estrella Immunopharma Secures $8 Million in Funding to Advance Cancer Therapy Programs - citybuzz -
Estrella Immunopharma completes $8M direct offering financing - TipRanks
Estrella Immunopharma Announces Closing of $8.0 Million Registered Direct Offering and Concurrent Private Placement - MEXC
Estrella Immunopharma Signs Multiple Material Agreements - TradingView — Track All Markets
Estrella Immunopharma closes $8 million registered direct offering - Investing.com
Estrella Immunopharma closes $8 million registered direct offering By Investing.com - Investing.com India
Estrella Immunopharma raises $8 million through registered offering By Investing.com - Investing.com Nigeria
Estrella Immunopharma stock falls after announcing $8 million offering - Investing.com India
Estrella Immunopharma raises $8 million through registered offering - Investing.com
Estrella Immunopharma, Inc. Announces $8.0 Million Registered Direct Offering and Concurrent Private Placement Priced At-the-Market Under Nasdaq Rules - The AI Journal
Short Interest in Estrella Immunopharma, Inc. (NASDAQ:ESLA) Grows By 28.5% - MarketBeat
Aug Levels: How Estrella Immunopharma Inc stock reacts to global recession fearsMarket Performance Recap & Low Drawdown Momentum Trade Ideas - Bộ Nội Vụ
Estrella Immunopharma (ESLAW) Stock Analysis Report | Financials & Insights - Benzinga
Estrella Immunopharma shares gain as CD19 cancer therapy progresses into phase II - MSN
Estrella Immunopharma offers up to 2.5 mln shares for resale by selling stockholders - marketscreener.com
Estrella Immunopharma Files for Secondary Offering - marketscreener.com
Investment Review: How interest rate cuts could boost Estrella Immunopharma Inc. stock2025 AllTime Highs & Free Growth Oriented Trading Recommendations - Улправда
Why Estrella Immunopharma Inc. stock remains on buy listsVolume Spike & Free Technical Pattern Based Buy Signals - Улправда
Is Estrella Immunopharma Inc. stock affected by interest rate hikes - Улправда
Is Estrella Immunopharma Inc. stock a safe haven assetEarnings Recap Report & Accurate Buy Signal Alerts - Улправда
Insider Buy: Is Estrella Immunopharma Inc. stock a safe haven asset2025 Breakouts & Breakdowns & High Conviction Buy Zone Picks - Улправда
Estrella Immunopharma (NASDAQ:ESLA) Trading 1.3% HigherHere's Why - MarketBeat
Levels Update: How interest rate cuts could boost Estrella Immunopharma Inc. stockWeekly Stock Recap & Verified Swing Trading Watchlists - ulpravda.ru
Estrella Immunopharma (NASDAQ:ESLA) & Foghorn Therapeutics (NASDAQ:FHTX) Head-To-Head Contrast - Defense World
Estrella Immunopharma advances STARLIGHT-1 trial after DSMB review - MSN
Estrella Immunopharma secures $3.35M in financing to advance clinical triall; shares up - MSN
Estrella Immunopharma (ESLA) Stock Analysis Report | Financials & Insights - Benzinga
Estrella’s EB103 advances to Phase II after positive safety data By Investing.com - Investing.com Nigeria
Estrella Immunopharma Advances STARLIGHT-1 Trial to Phase II - TradingView — Track All Markets
Estrella Immunopharma stock rises as cancer therapy advances to Phase II - Investing.com Canada
Estrella Immunopharma Inc Stock (ESLA) Financials Data
Revenue
Net Income
Cash Flow
EPS
2.92%
2.36%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):